Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, companion diagnostic test to be made widely available in Europe to aid in identifying epithelial ovarian cancer, or EOC, patients who may be eligible for targeted treatment with Elahere. Elahere is an antibody-drug conjugate therapy developed by AbbVie for the treatment of FRa-positive platinum-resistant ovarian cancer. This certification follows the news earlier this year that the Ventana FOLR1 test had received pre-authorization in Germany and Austria. This exceptional decision allowed clinicians and patients in these countries to access the test ahead of the CE Mark certification.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-movingbreaking financial news Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- Genentech terminates agreement for Nykode cancer vaccine program
- Genentech to present blood disorders data at ASH
- Roche downgraded to Hold from Buy at Erste Group
- Roche announces phase III INAVO120 results were published
- Roche price target raised to CHF 250 from CHF 235 at Deutsche Bank
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
